RxDoctor Payments DataLook up a doctor →

Dilawar Ajani, MD

Internal Medicine · Houston, TXNPI 1528047115

Payments from drug & device makers

$2,652,359in general payments, 2019–2025

Across 660 payments — averaging $4018.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironwood Pharmaceuticals, Inc$868K
  • GSK$439K
  • Endo Pharmaceuticals Inc.$279K
  • Pfizer$239K
  • Evofem Biosciences, Inc.$214K
  • Novartis$191K
  • plus $423K from 34 others
$84,599in research payments, 2019–2025

Across 18 payments — averaging $4699.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Motive Health, Inc.$65K
  • Vifor (international) Ltd.$18K
  • AbbVie$986

What the payments were for

  • Food & beverage$5,83399%
  • Education$581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,652,359 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$44,124
Medicare patients
101
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide29$36,776
OzempicSemaglutide13$26,482
JanuviaSitagliptin Phosphate21$25,986
JanumetSitagliptin Phos/Metformin Hcl16$25,047
EliquisApixaban28$23,550
VascepaIcosapent Ethyl46$21,519
JardianceEmpagliflozin20$18,959
TrulicityDulaglutide12$16,226
LinzessLinaclotide17$13,390
SuboxoneBuprenorphine Hcl/Naloxone Hcl18$10,996
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$9,805
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl31$4,686
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,184
Candesartan Cilexetil16$2,287
Levothyroxine Sodium230$1,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$404$53,00241 claims
MerckJanuvia, Janumet$221$51,03337 claims
Novo NordiskOzempic$397$26,48213 claims
PfizerEliquis$239,077$23,55028 claims
Boehringer IngelheimJardiance$477$18,95920 claims
AbbVieLinzess, Synthroid$43,349$14,22138 claims
GSKTrelegy Ellipta$438,729$9,80517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →